

ELI Lilly & Co. (LLY)

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000059478

ELI Lilly & Co. LLY; healthcare	
Grade	C A B C D E middle fifth of 371 graded peers percentile 55.7; sampling error 2.5 points; lower is stronger
Rank	207 of 371
Profitability	C percentile 55.5
Solvency	D/E percentile 78.6
Growth and financing	A percentile 15.3
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over \$2.67B assets total assets \$112.5B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress
Inputs computable	7 of 14
Graded from	filings received through Feb 12, 2026 239 days before the rescans; latest periodic filing 10-Q received Aug 5, 2026
Last close	\$1,169.61 2026-10-08; market equity \$1.1T
Price used in grade	None



C, the tortoise

middle fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans


split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: D from Jun 21, 2025, C from Feb 21, 2026, C/D from Apr 21, 2026, C from Aug 21, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 12, 2026

Eli Lilly and Company (referred to as the company, Lilly, we, or us) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop, manufacture, and market products in a single business segment-human pharmaceutical products. Our purpose is to unite caring with discovery to create medicines that make life better for people around the world. Our long-term success depends on our ability to continually discover or

acquire, develop, and commercialize innovative medicines.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 55.5						
Gross profitability		48.1%	32.2%	24.5	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		4.0%	(6.6%)	87.0	811	2025-12-31
Gross margin stability, five years		3.2 pts	2.8 pts	55.0	243	2025-12-31
Solvency, sleeve percentile 78.6						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-prime		not computable	(0.31)			one or more required annual facts are missing
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		1.58x	2.96x	78.6	839	2025-12-31
Growth and financing, sleeve percentile 15.3						
Revenue growth, three-year compound		31.7%	10.0%	20.8	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 0
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		31.5%	2.1%	15.1	704	2025-12-31
Net share issuance, one year		(0.5%)	2.5%	10.0	634	2026-02-09

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
202	Emergent BioSolutions Inc. (EBS)	54.3	C	
203	Abbott Laboratories (ABT)	54.6	C	
204	Teladoc Health, Inc. (TDOC)	54.9	C	fortress
				balance sheet
205	Neuronetics, Inc. (STIM)	55.1	C	
206	Regenxbio Inc. (RGNX)	55.4	C	short runway
207	ELI Lilly & Co. (LLY) <	55.7	C	
208	Cabaletta Bio, Inc. (CABA)	55.9	C	dilution
209	AdaptHealth Corp. (AHCO)	56.2	C	
210	Inogen Inc. (INGN)	56.5	C	fortress
				balance sheet
211	Cooper Companies, Inc. (COO)	56.8	C	
212	Aquestive Therapeutics, Inc. (AQST)	57.0	C	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	52.6%	8.0%	78
Distance from 52-week high	(8.6%)	(31.4%)	87
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.03	0.28	16
Sales to price	0.06	0.31	18
Composite equity issuance, five years	(7.1%)	20.3%	18
Relative strength against the sector, log excess return	0.21	(0.14)	78

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 7 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$8.9B
Operating cash flow, four quarters	\$28.1B
Months of runway	not finite
Days since last periodic filing	65 (10-Q received Aug 5, 2026)

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:Revenues	\$65.2B	2025-12-31	2026-02-12	10-K	0000059478-26-000013
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$11.1B	2025-12-31	2026-02-12	10-K	0000059478-26-000013
3	assets	us-gaap:Assets	\$112.5B	2025-12-31	2026-02-12	10-K	0000059478-26-000013
4	net income	us-gaap:NetIncomeLoss	\$20.6B	2025-12-31	2026-02-12	10-K	0000059478-26-000013
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$16.8B	2025-12-31	2026-02-12	10-K	0000059478-26-000013
6	assets	us-gaap:Assets	\$78.7B	2024-12-31	2026-02-12	10-K	0000059478-26-000013
7	revenue	us-gaap:Revenues	\$45.0B	2024-12-31	2026-02-12	10-K	0000059478-26-000013
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$8.4B	2024-12-31	2026-02-12	10-K	0000059478-26-000013
9	revenue	us-gaap:Revenues	\$34.1B	2023-12-31	2026-02-12	10-K	0000059478-26-000013
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$7.1B	2023-12-31	2026-02-12	10-K	0000059478-26-000013
11	revenue	us-gaap:Revenues	\$28.5B	2022-12-31	2025-02-19	10-K	0000059478-25-000067
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$6.6B	2022-12-31	2025-02-19	10-K	0000059478-25-000067
13	revenue	us-gaap:Revenues	\$28.3B	2021-12-31	2024-02-21	10-K	0000059478-24-000065
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$7.3B	2021-12-31	2024-02-21	10-K	0000059478-24-000065
15	current assets	us-gaap:AssetsCurrent	\$55.6B	2025-12-31	2026-02-12	10-K	0000059478-26-000013
16	current liabilities	us-gaap:LiabilitiesCurrent	\$35.2B	2025-12-31	2026-02-12	10-K	0000059478-26-000013
17	assets	us-gaap:Assets	\$64.0B	2023-12-31	2025-02-19	10-K	0000059478-25-000067
18	assets	us-gaap:Assets	\$49.5B	2022-12-31	2024-02-21	10-K	0000059478-24-000065
19	shares outstanding	dei:EntityCommonStockSharesOutstanding	943,357,420	2026-02-09	2026-02-12	10-K	0000059478-26-000013
20	shares outstanding	dei:EntityCommonStockSharesOutstanding	948,169,999	2025-02-14	2025-02-19	10-K	0000059478-25-000067